MKI67 and diffuse large B-cell lymphoma: Some studies have shown that R‐EPOCH or other dose‐intensified regimens improved the prognosis of certain DLBCL subgroups, such as DE, DT/TH, high‐risk young, or high Ki‐67 expression subgroups.29, 30, 31, 32, 33